Home » Stocks » NTRP

Neurotrope, Inc. (NTRP)

Dec 2, 2020 - NTRP merged into PTPI
Stock Price: $0.941 USD -0.109 (-10.38%)
Updated Dec 1, 2021 4:00 PM EST
Market Cap 22.39M
Revenue (ttm) n/a
Net Income (ttm) -12.35M
Shares Out 23.78M
EPS (ttm) -0.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Dec 1, 2021
Last Price $0.941
Previous Close $1.050
Change ($) -0.109
Change (%) -10.38%
Day's Open 1.040
Day's Range 0.915 - 1.040
Day's Volume 500,213
52-Week Range 0.713 - 1.470

News

Hide News
PRNewsWire - 5 months ago

NEW YORK and MANALAPAN TOWNSHIP, N.J., Sept. 30, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company focused o...

PRNewsWire - 9 months ago

NEW YORK and MANALAPAN TOWNSHIP, N.J., May 18, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company ("Metuchen"...

Benzinga - 1 year ago

Shares of thinly-traded microcap biopharma Neurotrope Inc (NASDAQ: NTRP) gap-opened sharply higher on above 50 times average volume following a corporate update from the company.

24/7 Wall Street - 1 year ago

It may be unusual to see a stock rise close to 100% without a corporate buyout, but in biotech and emerging pharmaceutical companies gains of that size can occur simply with a drug study updat...

Market Watch - 1 year ago

Shares of Neurotrope Inc. NTRP, -77.95% plummeted 79% on heavy volume Monday, to below the $1 mark for the first time in six years, after the biopharmaceutical company said its Alzheimer's dis...

Benzinga - 1 year ago

Shares of thinly-traded nano-cap biotech Neurotrope Inc (NASDAQ: NTRP) were plummeting Monday following an adverse clinical trial readout.

Zacks Investment Research - 1 year ago

Neurotrope has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Neurotrope (NTRP) stock based on the movements in the options market lately.

24/7 Wall Street - 1 year ago

The biotechnology sector is generally considered the most volatile and riskiest sector within all of healthcare.

Other stocks mentioned: AVXL
24/7 Wall Street - 1 year ago

Neurotrope, Inc. may be a winner by default in the battle against Alzheimer’s disease after shares of Biogen Inc. suffered handily with the announcement that it and partner Eisei were halting ...

About NTRP

Neurotrope, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Jun... [Read more...]

Industry
Biotechnology
Founded
2012
CEO
Charles Ryan
Employees
5
Stock Exchange
NASDAQ
Ticker Symbol
NTRP
Full Company Profile

Financial Performance

Financial Statements